Brief: Everest Medicines Says Licensing Partner Calliditas Therapeutics Announced U.S. FDA Approved Nefecon Delayed Release Capsules
21/12/2023 02:34
Dec 20 (Reuters) - Everest Medicines Ltd 1952.HK :
* EVEREST MEDICINES - LICENSING PARTNER CALLIDITAS
THERAPEUTICS
ANNOUNCED U.S. FDA APPROVED NEFECON DELAYED RELEASE CAPSULES
Source text for Eikon: ID:nPn46yBW5a
Further company coverage: 1952.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations